Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 3
2006 2
2007 7
2008 6
2009 3
2010 6
2011 3
2012 4
2013 8
2014 10
2015 23
2016 16
2017 16
2018 12
2019 12
2020 10
2021 9
2022 12
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25886003

154 results

Results by year

Filters applied: . Clear all
Page 1
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Breast Cancer Res Treat. 2007 Mar;101(3):249-57. doi: 10.1007/s10549-006-9295-8. Epub 2006 Sep 28. Breast Cancer Res Treat. 2007. PMID: 17006756
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Cui X, et al. Mol Endocrinol. 2003 Apr;17(4):575-88. doi: 10.1210/me.2002-0318. Epub 2003 Jan 2. Mol Endocrinol. 2003. PMID: 12554765
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Creighton CJ, et al. Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22. Breast Cancer Res. 2010. PMID: 20569503 Free PMC article.
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Tobin NP, et al. Ann Oncol. 2015 Jan;26(1):81-88. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31. Ann Oncol. 2015. PMID: 25361981 Free PMC article. Clinical Trial.
154 results